MedTrace Logo

Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

NCT02083133 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 496

Last updated 2023-06-22

No results posted yet for this study

Summary

The purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (CrCl) ≤15 mL/min or on hemodialysis results in an increased number of hypoglycemic episodes.

Conditions

Sponsors & Collaborators

  • Cook County Health

    lead OTHER_GOV

Principal Investigators

  • Pete Antonopoulos, PharmD · Cook County Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2017-01-15
Completion
2017-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083133 on ClinicalTrials.gov